Primary Risk Drivers
Below is a snapshot of domains that materially influence the MARA Rating.
Clinical effectiveness
The clinical trial evidence suggests that latanoprost-netarsudil is as effective as bimatoprost-timolol, demonstrating non-inferiority. However, indirect comparisons with other fixed-dose combination treatments are highly uncertain, indicating comparable efficacy but lacking definitive superiority.
Cost effectiveness
Latanoprost-netarsudil is associated with similar or lower costs compared to most branded and some generic fixed-dose combination treatments. The cost-comparison analysis indicates it is likely to be cost-effective, aligning with common thresholds.
Quality of life
The document discusses the significant impact of glaucoma and ocular hypertension on quality of life, highlighting the burden of multiple treatments. The introduction of latanoprost-netarsudil as a once-daily treatment option is expected to alleviate some of these burdens, thus providing moderate improvements in HRQoL.
Supporting Domains
Safety and Adverse Effects
The safety profile of latanoprost-netarsudil is acceptable, with mild adverse effects such as eye redness reported. These effects are generally manageable and reversible, indicating a good tolerability compared to existing treatments.
Comparator Selection
The evaluation committee concluded that all fixed-dose combination eye drops should be considered relevant comparators for latanoprost-netarsudil, indicating a strong selection of comparators that reflect current clinical practice.
Patient Population and Subgroups
The trial population adequately reflects the licensed population for latanoprost-netarsudil, and the document indicates that the patient population is representative of those with primary open-angle glaucoma or ocular hypertension.
Care Pathway Integration
Latanoprost-netarsudil is expected to integrate well into existing treatment pathways, requiring only minor adjustments. It is positioned as a treatment option after other therapies have failed, which aligns with current clinical practices.
Resource Use and Cost Implications
The economic model indicates that latanoprost-netarsudil has a manageable budget impact and is likely to be resource-efficient compared to existing treatments, supporting its adoption in clinical practice.
Evidence Quality and Robustness
The evidence base includes a phase 3 RCT (MERCURY 3) demonstrating non-inferiority to a comparator, although there are some concerns regarding the indirect comparisons made. Overall, the evidence is robust but has some limitations.
Uncertainty, Sensitivity, and Broader Impacts
While there are uncertainties related to the indirect comparisons and the economic model, the overall context of unmet need and the potential benefits of a new treatment option mitigate some of these concerns.
